Daniel Getts, Myeloid Therapeutics CEO

Ex­clu­sive: Myeloid Ther­a­peu­tics rais­es $73M, bring­ing in ARCH ahead of in vi­vo pro­gram en­ter­ing the clin­ic

Myeloid Ther­a­peu­tics has raised a $73 mil­lion Se­ries A2 round that brings ARCH Ven­ture Part­ners in as a new in­vestor, as the biotech pre­pares to en­ter the clin­ic with its first in vi­vo mR­NA pro­gram tar­get­ing myeloid cells.

Myeloid was start­ed in 2019 to ex­plore the idea of mak­ing drugs cen­tered on myeloid cells, or the white blood cells that play a front­line role in the im­mune re­sponse.

Co-found­ed by the bio­chemist Ronald Vale and on­col­o­gist Sid­dhartha Mukher­jee, among oth­ers, Myeloid is based on re­search show­ing these im­mune cells play a key role in cer­tain types of tu­mors. Since pub­licly launch­ing in Jan­u­ary 2021 with a $50 mil­lion Se­ries A round, the biotech now has 42 em­ploy­ees, CEO Daniel Getts told End­points News, with plans to grow to rough­ly 50 peo­ple over the next 12 months. Its drug can­di­date is al­ready pro­duc­ing en­cour­ag­ing — al­beit very ear­ly — clin­i­cal re­sults.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.